P/E at 36.33 vs Industry's 35.27: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflects Confidence but Warrants Scrutiny

The current P/E of 36.33 for Sun Pharmaceutical Industries Ltd is a 3.1% premium over the industry average of 35.27. While not an extreme divergence, this premium suggests that investors are willing to pay slightly more for the company’s earnings compared to its sector peers. This could be attributed to Sun Pharma’s large-cap status, market leadership, and consistent earnings growth. However, the premium also invites questions about whether the stock’s valuation is fully justified by its fundamentals or if it is partly driven by market sentiment — previously rated Hold, what is Sun Pharma’s current rating? The P/E premium is a critical metric to watch in the context of the company’s recent performance and sector dynamics.

Performance Across Timeframes: Consistent Outperformance Against Sensex

Examining the stock’s returns reveals a strong performance relative to the broader market. Over one year, Sun Pharmaceutical Industries Ltd has gained 14.06%, while the Sensex declined by 7.98%. This outperformance extends to shorter periods as well: the stock is up 10.73% over three months versus a marginal 0.31% gain for the Sensex, and 6.87% over one month compared to the Sensex’s 3.99%. Year-to-date, the stock has appreciated 10.57%, contrasting with the Sensex’s 9.80% decline. Even on a daily and weekly basis, the stock has outpaced the index, with gains of 0.72% and 1.61% respectively, compared to the Sensex’s 0.48% and -0.82%. This consistent alpha generation across multiple timeframes highlights the stock’s resilience and relative strength — is this momentum sustainable or a temporary phase?

Moving Average Configuration: Bullish Technical Setup Across All Key Averages

The technical picture for Sun Pharmaceutical Industries Ltd is notably positive. The stock is trading above all major moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong uptrend across short, medium, and long-term horizons. This comprehensive bullish configuration suggests that recent gains are supported by sustained buying interest and momentum. The stock is also trading just 1.64% below its 52-week high of Rs 1929, indicating proximity to its peak levels over the past year. After two consecutive days of decline, the stock reversed course with a 0.72% gain today, outperforming the sector by 0.31%, which may hint at renewed investor confidence. The alignment above all moving averages is often interpreted as a sign of trend continuation rather than a short-lived bounce — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Performance Context: Pharmaceuticals & Biotechnology Showing Mixed Results

The Pharmaceuticals & Biotechnology sector, to which Sun Pharmaceutical Industries Ltd belongs, has exhibited a mixed performance recently. While some companies have posted positive returns, others have remained flat or declined, reflecting the sector’s sensitivity to regulatory developments, patent expiries, and global demand fluctuations. Sun Pharma’s ability to outperform the sector and the broader market over multiple timeframes underscores its relative strength within this challenging environment. The stock’s premium valuation compared to the industry P/E may partly reflect this leadership position — how does this premium align with sector-wide risks and opportunities?

Rating Reassessment: Previously Rated Hold, Now Updated

On 8 June 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from its previous Hold status. While the current rating is not disclosed, the reassessment reflects a comprehensive review of the company’s fundamentals, valuation, technicals, and sector positioning. The Mojo Score stands at 74.0, indicating a favourable overall assessment. This rating update comes amid the stock’s sustained outperformance and positive technical signals, suggesting a shift in the analytical view — should investors in Sun Pharma hold, buy more, or reconsider?

Long-Term Returns: Strong Track Record with Some Relative Lag Over a Decade

Looking beyond the recent year, Sun Pharmaceutical Industries Ltd has delivered robust returns over three and five years, with gains of 83.64% and 184.73% respectively, significantly outperforming the Sensex’s 17.75% and 46.73% over the same periods. However, over a ten-year horizon, the stock’s 144.25% return trails the Sensex’s 183.36%, indicating some relative underperformance in the longer term. This divergence may reflect sector-specific challenges or company-specific cycles. The recent positive momentum and technical strength could signal a potential shift in this trend, but the valuation premium warrants careful consideration — is the current valuation justified by the long-term growth prospects?

Market Capitalisation and Sector Positioning

With a market capitalisation of approximately Rs 4,56,257.54 crore, Sun Pharmaceutical Industries Ltd firmly holds its place as a large-cap leader in the Pharmaceuticals & Biotechnology sector. This scale provides the company with competitive advantages in research, development, and global reach. The stock’s ability to maintain a premium valuation relative to the industry P/E reflects this leadership, but also raises questions about the sustainability of such a premium in a sector prone to regulatory and patent risks.

Conclusion: Data Reflects a Stock with Strong Momentum and a Slight Valuation Premium

The data for Sun Pharmaceutical Industries Ltd paints a picture of a stock that has consistently outperformed the broader market and its sector peers over multiple timeframes. Trading at a modest premium to the industry P/E, the stock benefits from a bullish technical setup, trading above all major moving averages and near its 52-week high. The recent rating reassessment from Hold reflects this evolving outlook. However, the premium valuation and mixed long-term relative returns suggest that investors should carefully weigh the stock’s current momentum against sector risks and valuation considerations — what is the current rating for Sun Pharmaceutical Industries Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →